Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 RELATIVITY-098 trial evaluating Opdualagâ„¢ (nivolumab and relatl ...
pharmaphorum8d
BMS extends its cost-cutting drive by another $2bn
BMS acquired Cobenfy as part of its $14 billion takeover of Karuna Therapeutics towards the end of 2023, and analysts at ...
Bristol Myers’ Phase 3 RELATIVITY-098 for Opdualag did not meet primary endpoint
Bristol Myers Squibb announced the Phase 3 RELATIVITY-098 trial evaluating Opdualag (nivolumab and relatlimab-rmbw) for the adjuvant treatment of patients wi ...
PMLiVE10d
BMS receives CHMP recommendation for Opdivo/Yervoy combination in liver cancer
Dana Walker, vice president, Opdivo global programme lead, BMS, said: “HCC is the predominant type of liver cancer globally, including in the EU, and when diagnosed at the advanced or unresectable ...
precisionmedicineonline7d
Bristol Myers Squibb Focused on Opdivo SubQ Growth as Q4 Precision Product Sales Increase
Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.
Targeted Oncology18h
Post–PD-1 Data in Melanoma Offers Insight into IO Approaches
During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed goals and barriers to treatment when using ...
Hosted on MSN7d
Nivolumab Added to Chemo Improves Response in ER+, HER2− Breast Cancer
For patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 ...
PMLiVE8d
BMS receives CHMP recommendation for Breyanzi in follicular lymphoma
The Committee for Medicinal Products for Human Use (CHMP) has recommended that the CD19-directed CAR T cell therapy, which is already approved in the EU for certain lymphomas, be authorised to treat ...